Clinical Trial

A New Diagnostic Paradigm for Retinitis Pigmentosa Secondary to USH2A Pathogenic Variants

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
Aim of the study is to perform a non-invasive multimodal retinal imaging investigation in a cohort of patients affected by USH2A retinitis pigmentosa (USH2A-RP), in order to develop a new diagnostic paradigm to categorize clinically relevant subgroups. All the procedures will be performed according to normal clinical practice. In addition, a novel quantitative profiling of serum microRNAs will be carried out in order to analyze the clinical importance of microRNA biomarkers in the clinical setting of the disease.
Trial Details
NCT Number NCT06545253
Lead Sponsor IRCCS Ospedale San Raffaele
Conditions USH2A Variant Retinitis Pigmentosa
Enrollment 60 participants
Start Date 2024-08
Primary Completion 2025-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2024-08-09